Symphony Evolution, Inc. is a biopharmaceutical company formed to collaborate with Exelixis, Inc. (NASDAQ: EXEL) on the clinical development of three clinical stage programs: XL647 and XL999 targeted anti-cancer agents, through Phase I and Phase II studies in multiple tumor types; and XL784 in diabetic nephropathy, through Phase I and Phase II studies.
|
